002900 Stock Overview
Engages in the research, development, production, and sale of pharmaceutical product and medical devices in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Harbin Medisan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.93 |
| 52 Week High | CN¥14.40 |
| 52 Week Low | CN¥7.81 |
| Beta | 0.42 |
| 1 Month Change | 2.90% |
| 3 Month Change | -11.65% |
| 1 Year Change | 22.44% |
| 3 Year Change | -37.31% |
| 5 Year Change | -19.07% |
| Change since IPO | -42.76% |
Recent News & Updates
Recent updates
Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Shares Climb 25% But Its Business Is Yet to Catch Up
Nov 11
Harbin Medisan Pharmaceutical (SZSE:002900) Posted Weak Earnings But There Is More To Worry About
Sep 05Harbin Medisan Pharmaceutical (SZSE:002900) Will Pay A Larger Dividend Than Last Year At CN¥0.20
Jun 01Is Harbin Medisan Pharmaceutical (SZSE:002900) A Risky Investment?
May 23Harbin Medisan Pharmaceutical Co., Ltd.'s (SZSE:002900) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Mar 08Shareholder Returns
| 002900 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.1% | 1.7% | 3.3% |
| 1Y | 22.4% | 4.3% | 19.0% |
Return vs Industry: 002900 exceeded the CN Pharmaceuticals industry which returned 3.4% over the past year.
Return vs Market: 002900 exceeded the CN Market which returned 17.4% over the past year.
Price Volatility
| 002900 volatility | |
|---|---|
| 002900 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.6% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 002900 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002900's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 2,115 | Jian Fei Qin | www.medisan.com.cn |
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical product and medical devices in China. The company offers various drugs for nervous system, cardiovascular system, musculoskeletal system, systemic anti-infective, basic infusions, nutritional infusion, anti-tumor and immunomodulators, digestive tract, metabolism, etc. It also produces and sells cosmetics. Harbin Medisan Pharmaceutical Co., Ltd.
Harbin Medisan Pharmaceutical Co., Ltd. Fundamentals Summary
| 002900 fundamental statistics | |
|---|---|
| Market cap | CN¥3.07b |
| Earnings (TTM) | CN¥54.12m |
| Revenue (TTM) | CN¥1.10b |
56.8x
P/E Ratio2.8x
P/S RatioIs 002900 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002900 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.10b |
| Cost of Revenue | CN¥538.36m |
| Gross Profit | CN¥564.50m |
| Other Expenses | CN¥510.37m |
| Earnings | CN¥54.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 51.19% |
| Net Profit Margin | 4.91% |
| Debt/Equity Ratio | 42.2% |
How did 002900 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield112%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 06:22 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harbin Medisan Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiaxi Xu | Industrial Securities Co. Ltd. |